PLoS ONE · 2011 · 104 citations · 29 references
Life SciencesBiochemistryMolecular BiologyMolecular DiagnosticsProtein BiochemistryProteomicsBiomarker DiscoveryClinical ProteomicsMolecular ScreeningProtein QuantificationProteomic BiomarkersDiagnostic BiomarkersNext-generation Sequencing BiomarkersPlasma Protein BiomarkersPlasma ProteomicsProtein Biomarker ScreeningProtein Biomarker ValidationProtein BiomarkersValidation Of Diagnostic Markers
Despite intense interest, methods enabling highly sensitive, specific parallel measurement of many protein biomarkers are lacking, and two newly identified proteins (Cystatin‑B and Kallikrein‑6) have not yet been reported and require validation in larger cohorts. The study introduces ProteinSeq, a multiplex proximity ligation assay read out by real‑time PCR or DNA sequencing. ProteinSeq was applied to plasma from cardiovascular disease patients and matched controls, measuring protein levels via proximity ligation followed by PCR or sequencing. ProteinSeq achieved higher sensitivity than conventional sandwich assays for 35 proteins in 5 µl plasma, showed minimal background increase with multiplexing, and identified P‑selectin, Cystatin‑B, and Kallikrein‑6 as putative CVD biomarkers, indicating its promise for large‑scale protein screening and clinical validation.
Despite intense interest, methods that provide enhanced sensitivity and specificity in parallel measurements of candidate protein biomarkers in numerous samples have been lacking. We present herein a multiplex proximity ligation assay with readout via realtime PCR or DNA sequencing (ProteinSeq). We demonstrate improved sensitivity over conventional sandwich assays for simultaneous analysis of sets of 35 proteins in 5 µl of blood plasma. Importantly, we observe a minimal tendency to increased background with multiplexing, compared to a sandwich assay, suggesting that higher levels of multiplexing are possible. We used ProteinSeq to analyze proteins in plasma samples from cardiovascular disease (CVD) patient cohorts and matched controls. Three proteins, namely P-selectin, Cystatin-B and Kallikrein-6, were identified as putative diagnostic biomarkers for CVD. The latter two have not been previously reported in the literature and their potential roles must be validated in larger patient cohorts. We conclude that ProteinSeq is promising for screening large numbers of proteins and samples while the technology can provide a much-needed platform for validation of diagnostic markers in biobank samples and in clinical use.
29
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Larry Gold, Deborah Ayers, Jennifer Bertino et al. · PLoS ONE · 2010 · 1.7K citations · Full text
Protein detection using proximity-dependent DNA ligation assays
Simon Fredriksson, Mats Gullberg, Jonas Jarvius et al. · Nature Biotechnology · 2002 · 1.5K citations
A decade’s perspective on DNA sequencing technology
Elaine R. Mardis · Nature · 2011 · 915 citations